For example, in the Phase III clinical trial, the median OS for patients with recurrent glioblastoma was almost the same between the group treated with nivolumab (anti-PD-1) and the group treated with bevacizumab (anti-VEGF), which inhibits tumor growth by targeting neovascularization endotheliocytes, leading to the disruption of the tumor’s blood supply [162]. This evidence concerns the gene VEGFA and neoplasm.